Neuroprotective Effects of Lacosamide in Experimental Traumatic Spinal Cord Injury in Rats

Serdar DEMIROZ, Koray UR, Aykut ULUCAN, Aydin Sukru BENGU, Feyza DEMIRALIN UR, Ozlem Oz GERGIN, Sevki ERDEM

1Bingol State Hospital, Department of Orthopaedics and Traumatology, Bingol, Turkey
2Bingol State Hospital, Department of Neurosurgery, Bingol, Turkey
3Bingol University Vocational School of Health Services, Department of Medical Services and Techniques, Pathology Laboratory Programme, Bingol, Turkey
4Bingol University Vocational School of Health Services, Department of Medical Services and Techniques, Medical Laboratory Programme, Bingol, Turkey
5Bingol State Hospital, Department of Neurology, Bingol, Turkey
6Kayseri Education and Research Hospital, Department of Anesthesiology and Reanimation, Kayseri, Turkey
7Medicana Kadikoy Hospital, Department of Orthopaedics and Traumatology, Istanbul, Turkey

Corresponding author: Serdar DEMIROZ serdardemiroz@hotmail.com

ABSTRACT

AIM: To evaluate the effects of lacosamide on traumatic spinal cord injury (SCI) in rats.

MATERIAL and METHODS: A total of 28 male Wistar albino rats, each weighing 300–350 g, were included. They were randomly assigned to four groups. In Group 1, only a laminectomy was performed; in Group 2, SCI was performed after laminectomy; in Group 3, SCI was performed after laminectomy followed by lacosamide administration, and in Group 4, SCI was performed after laminectomy followed by physiological saline administration. After 48 hours, all animals were sacrificed, blood samples were drawn, and their spinal cords were removed. The serum levels of catalase, glutathione peroxidase (GPx), superoxide dismutase (SOD) and malondialdehyde (MDA) were measured, and the spinal cord specimens were examined for neuronal degeneration (PND).

RESULTS: The MDA level was the lowest and the antioxidant enzyme levels were the highest in Group 3. There were statistically significant differences between Group 3 and the others in their PND score, serum MDA, SOD, GPx and catalase levels (p<0.05).

CONCLUSION: Lacosamide has a neuroprotective effect in SCI in rats that is related to its ability to decrease the production of reactive oxygen species by increasing antioxidant enzyme expression, inhibit lipid peroxidation and attenuate glial cell activation.

KEYWORDS: Lacosamide, Spinal cord injury, Neuroprotective agents, Oxidative stress, Rat

INTRODUCTION

Traumatic spinal cord injury (SCI) is a catastrophic event that results in disparate outcomes ranging from complete recovery to paraplegia, tetraplegia or death (21). In humans, SCI is most commonly caused by a combination of acute impact and persistent compression and shows two consecutive stages (5). First, the vertebral fracture fragments lead to contusion and compression of the spinal cord, which is called primary injury. Thereafter, the secondary injury follows, which is characterised by ischemic dysfunction, inflammation, occurrence of oxygen-free radicals, lipid peroxidation and apoptosis (6,10,23,29). This secondary injury has been the therapeutic target in most studies designed to determine whether pharmacologic agents have neuroprotective effects after SCI (3,19,26).
Several studies have investigated pharmacologic agents that were presumed to have neuroprotective effects after SCI, but only methylprednisolone has shown beneficial effects in large clinical studies (13-15,30,31,33). Although it has beneficial effects on parenchymal damage, there is no significant improvement of functional recovery (25).

Lacosamide is a new pharmaceutical candidate for neuroprotection after traumatic SCI. In addition to its antiepileptic function, lacosamide has been shown to protect nervous system tissue. It improves functional performance in rodent models after traumatic brain injury (12,22), and pretreatment with lacosamide has shown a neuroprotective effect after transient global cerebral ischaemia (1). This neuroprotective capacity has been linked to lacosamide’s anti-inflammatory properties and its ability to inhibit glial cell proliferation and lipid peroxidation, which are pathogenetic in the secondary injury phase of traumatic SCI (27). Therefore, we hypothesised that lacosamide may provide neuroprotective effects after traumatic SCI.

The purpose of the present study was to evaluate the effects of lacosamide on the injured spinal cord of rats and the serum levels of the antioxidant enzymes catalase, glutathione peroxidase (GPx) and superoxide dismutase (SOD), as well as the lipid peroxidation end-product malondialdehyde (MDA).

**MATERIAL and METHODS**

The study protocol was approved by the local ethics committee (29.12.2016; no: 07/04). A total of 28 male Wistar albino rats, each weighing 300–350 g, were included in this study. They were randomly split into four groups that received different treatments as follows: in Group 1, only a laminectomy was performed; in Group 2, SCI was imitated after laminectomy; in Group 3, lacosamide was administered after the SCI and in Group 4, physiological saline solution was administered instead.

The exact procedures were performed as follows: all rats were kept under environmentally controlled conditions. They were anaesthetised with an intraperitoneal injection of 10 mg/kg of xylazine (Alfazyne; Egevet, Izmir, Turkey) and 50 mg/kg of ketamine (Ketalor; Parke-Davis, Eczacibasi, Turkey). The rats were placed in the prone position, and their backs were shaved and cleaned with 10% polyvidone iodine (Batticon; Adeka, Samsun, Turkey). A midline skin incision was made from T7 to T12, the paravertebral muscles were dissected, and a total laminectomy was performed under the microscope at the level T10–11. After laminectomy, the surgical wound was closed in Group 1. After the same laminectomy, a vascular clip (Scanlan®Vascu-Statt®; Scanlan, SaintPaul, MN, USA) with a 40g closing force was applied to the spinal cord at level T10–11 in Group 2, and then the wound was closed. The rats in Group 3 received the same intervention before lacosamide was administered intraperitoneally at a dose of 30 mg/kg at 8-hour intervals. The first dose of drug administered immediately after closing the skin after spinal trauma and the last dose administered 8 hours before the sacrifice. Rats received a total of 7 doses of medication. In Group 4, physiological saline was administered at the same doses and intervals as the third group.

In all groups, we compressed the spinal cord for one minute, which was designed to be sufficient to cause mild to severe damage (Figure 1) (18).

Forty-eight hours after the injury, all animals were sacrificed by decapitation under deep anaesthesia and an autopsy performed according to the Virchow technique. A 5.0 mL blood sample was drawn for biochemical analysis, and the spinal cords were removed for histopathological examination. Blood samples were centrifuged at 1,500 rpm for 15 minutes to separate the serum, and serum samples were stored at −40°C before analysing the GPx, SOD, catalase and MDA levels, using a commercial enzyme-linked immunosorbent assay kit (SunRed; Sunred Biological Technology Co., Ltd., Shanghai, China; catalogue numbers SOD:201-11-0169; GPx:201-11-5104; catalase:201-11-5106; MDA:201-11-0157).

Spinal cord tissue samples were fixed in 10% buffered formaldehyde solution, processed using a routine dehydration protocol in ascending grades of ethanol, cleared in xylene and embedded in paraffin. Paraffin-embedded tissue samples were sectioned into 5-µm thick slices with a rotary microtome (RM2125; Leica, Wetzlar, Germany). The slides were stained with haematoxylin and eosin for histopathological examination. Finally, the slides were examined and photographed using a light microscope with an imaging system (DM2500/DFC295; Leica, Wetzlar, Germany). The histopathological findings including the extent of the inflammatory reaction were examined using light microscopy. The inflammatory reaction was assessed using an immunohistochemistry scoring system (modified Allred system) and revealed the presence of neuronal degeneration (PND). The PND score was considered as the ratio of the amount of glial cell proliferation to the normal tissue in the region of tissue damage and was classified into the following grades: negative=0; <1%=1; 1%–9% =2; 10%–32% =3; 33%–65% =4 and >65%=5 (9).

![Image](image-url)  
Figure 1: Illustration of the spinal cord injury induced in Wistar rats (n = 28): compression of the spinal cord with a clamp exerting a 40g closing force.
All data were analysed using SPSS Statistics for Windows, version 20.0 (IBM Corp., Armonk, NY, USA). The Mann-Whitney U test was used to compare the descriptive statistical measurements (mean, standard deviation, minimum and maximum) and the parameters that did not show a normal distribution in the quantitative data comparison. One-way analysis of variance was applied to assess the differences among the groups. Statistical significance was determined as p<0.05.

RESULTS
The spinal cord tissue showed a normal histological appearance in Group 1 (Figure 2A). In Group 2, severe perineural vacuolations of the motor nuclei of the neurons, neuronal shrinkage, loss of neurons, degeneration and necrosis of most of the neurons with pyknotic nuclei and diffuse haemorrhage, loss of grey matter and proliferation of glial cells around the central canal and dorsal horn were detected in the spinal cord (Figure 2B). The spinal cord tissue in Group 3 showed perineural vacuolation and degeneration of some neurons, neuronal shrinkage, haemorrhage with limited proliferation of glial cells around the central canal and dorsal horn (Figure 2C). The lesions and PND scores of the spinal cord tissues in Group 3 were lower than those of Group 2. The histopathologic findings in the white and grey matter in the rats’ spinal cords in Group 4 were similar to those in Group 2 (Figure 2D).

The PND scores of the spinal cord tissue for the four groups are shown in Table I. There was a statistically significant difference between both Groups 3 and 2 and Groups 3 and 4 (p<0.05).

Figure 2: Histopathology of the spinal cord tissues (light microscopy, ×100 magnification; haematoxylin and eosin staining). A) Group 1: normal histological structure of the medulla spinalis. B) Group 2: severe neuronal loss and proliferation of glial cells (arrow heads), diffuse spongious appearance (arrows) of white matter and diffuse haemorrhage (stars). C) Group 3: degeneration of neurons (left arrow heads), mild congestion (left arrows), proliferation of glial cells (right arrow heads) and spongious appearance (right arrows) of white matter. D) Group 4: severe neuronal loss and proliferation of glial cells (arrow heads), diffuse spongious appearance (arrows) of white matter and diffuse haemorrhage (stars).
Table I: Biochemical and Pathological Results Relevant to the Groups

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (sham)</th>
<th>Group 2 (SCI)</th>
<th>Group 3 (SCI + L)</th>
<th>Group 4 (SCI + PS)</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA (ng/mL)</td>
<td>1.18 ± 0.154</td>
<td>1.35 ± 0.070b</td>
<td>0.75 ± 0.220b,c</td>
<td>1.22 ± 0.149c</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>GPx (ng/mL)</td>
<td>0.64 ± 0.067</td>
<td>0.57 ± 0.027b</td>
<td>0.92 ± 0.038b</td>
<td>0.55 ± 0.049</td>
<td></td>
</tr>
<tr>
<td>SOD (ng/mL)</td>
<td>0.20 ± 0.038b</td>
<td>0.30 ± 0.062b</td>
<td>0.84 ± 0.234a,b,c</td>
<td>0.22 ± 0.049c</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Catalase (ng/mL)</td>
<td>0.60 ± 0.052</td>
<td>0.51 ± 0.025b</td>
<td>0.68 ± 0.035b</td>
<td>0.55 ± 0.049</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>PND</td>
<td>0</td>
<td>4.57 ± 0.202b</td>
<td>2.86 ± 0.404b,c</td>
<td>4.00 ± 0.309c</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>


*One-way ANOVA test, Group 1 vs Group 3 (p<0.05), Group 2 vs Group 3 (p<0.05), Group 3 vs Group 4 (p<0.05).

The serum GPx, SOD, catalase and MDA levels are also shown in Table I. There were statistically significant differences in the MDA levels between Groups 2 and 3 and Groups 3 and 4 (p<0.05). The MDA level was lowest in Group 3. The catalase level in Group 3 was higher than in all other groups, but the difference was only statistically significant between Groups 2 and 3 (p<0.05). The GPx level was also the highest in Group 3 with statistically significant differences in the levels between Groups 2 and 3 and Groups 2 and 4 (p<0.05). The SOD levels were also highest in Group 3, and there was a statistically significant difference between these levels and those of all other groups (p<0.05).

**DISCUSSION**

In the present study, we found that the MDA levels were the lowest and the antioxidant enzyme levels were the highest in Group 3, to whom lacosamide had been administered after SCI. There was a statistically significant difference between Groups 2 and 3 for the following parameters: PND score, serum MDA, SOD, GPx and catalase levels after traumatic SCI.

Initially, after SCI, the vertebral fragments lead to contusion and compression of the cord, which is called the primary injury. Consecutively, the secondary injury phase starts, which is characterised by ischemic dysfunction, inflammation, oxidative stress and neuronal injury. This phase may last for weeks. The primary injury occurs at the time of trauma, and there is little that can be done to prevent its immediate effects. On the other hand, the long secondary injury phase has become target for interventions with experimental substances to prevent SCI. To this end, protection against free radical-mediated oxidative stress and lipid peroxidation are the main therapeutic strategies (7,8,11,28). The neuroprotective effect of methylprednisolone, the only drug proven to be effective in large clinical studies, depends on its scavenger role for free oxygen radicals and its ability to inhibit lipid peroxidation.

To maintain normal cellular functions, a balance between oxidants and antioxidants is critical. In case of extreme oxidative stress, the oxidative damage outweighs the cellular antioxidant activity, which results in tissue injury (32). Reactive oxygen species (ROS) generated by oxidative stress are responsible for ongoing tissue injury. GPx, SOD and catalase are some of the antioxidant enzymes that protect against oxidative stress by inhibiting the production of ROS. SODs are a class of enzymes that catalyse the breakdown of the superoxide anion into oxygen and hydrogen peroxide. GPx reduces hydrogen peroxide and lipid peroxide to water and lipid alcohols. Catalases are also enzymes that catalyse the conversion of hydrogen peroxide to water and oxygen. If the activity of these enzymes is decreased, the amount of hydrogen peroxide increases, leading to direct tissue damage. After trauma, these enzymes are expected to increase as the body's defence system. This is why several studies in the literature examine the tissue and serum levels of these enzymes to assess the neuroprotective effect of drugs (17). Choi et al. reported increases of catalase and GPx expression after lacosamide pre-treatment that contributed to neuroprotection in experimentally induced transient cerebral ischaemia in gerbils (4). In our study, there was also an increase in GPx, SOD and catalase serum levels in the rats in Group 3 that had received lacosamide compared to all other groups, and the difference was statistically significant compared to the rats who did not receive lacosamide in Group 2. These results indicate a neuroprotective effect of lacosamide resulting from increased antioxidant enzyme activity.

Lipid peroxidation is another crucial step in the secondary injury phase after SCI (16,20). It results in the damage of membrane lipids by ROS, which leads to cellular dysfunction because of altered membrane fluidity and permeability (32). MDA is the final product of these reactions, and in cases of increased ROS, such as in trauma, the amount of MDA increases as a result of tissue damage. Therefore, MDA is widely used as a marker of SCI. Solmaz et al. reported the potential lipid peroxidation-inhibiting effect of lacosamide on rats in a study on sepsis-induced critical illness polyneuropathy (27). Although sepsis and trauma are two different conditions, lipid peroxidation plays an important role in the etiopathogenesis of both. Therefore, we suggest that lacosamide, which reduces lipid peroxidation, also has a protective effect in SCI. Consequently, the decrease in MDA serum levels was an expected result in Group 3 and supports our hypothesis of a neuroprotective effect of lacosamide in SCI.
Previous studies reported that there is an association between ischaemic stroke and glial cell activation (2,24). Furthermore, it was suggested that lacosamide was able to protect against ischemia-induced cell damage in neural tissue in the brain, and that this neuroprotective activity is associated with attenuation of glial cell activation (1). We also found that there was a lower PND score based on the microscopic examination of glial cell proliferation in Group 3 when compared with Groups 2 and 4, and it was statistically significant (p<0.05). Therefore, we suggest that lacosamide has a neuroprotective effect in SCI by inhibiting glial proliferation.

Our study has several limitations. We evaluated the antioxidant enzyme and MDA levels only in serum, not in the spinal cord tissue, as in many studies in the literature (3). Furthermore, there was no clinical evaluation of the rats after SCI and treatment. It might be a vital limitation of this study, but because we created only a mild damage to the spinal cord, most rats were ambulatory with only a mild deficiency, and there was no significant change in time to sacrifice. Scoring was not significant since it showed similar clinical features. Therefore, we thought that the histological and biochemical evaluation might be sufficient. Finally, there was a relatively short follow-up period.

**CONCLUSION**

This study is the first to investigate the neuroprotective effects of lacosamide after SCI. The results of the biochemical and histological analyses revealed that lacosamide has a neuroprotective effect after experimental SCI in rats. This neuroprotective effect is related to its ability to decrease ROS production by increasing antioxidant enzyme expression, inhibit lipid peroxidation and attenuate glial cell activation.

**REFERENCES**


Demiroz S. et al: Lacosamide Treatment After Spinal Cord Injury


